4 reasons to use metformin Review article
Article Sidebar
Published:
Jun 30, 2015
Keywords:
metformin, type 2 diabetes, pleiotropism, AMPK
Main Article Content
Abstract
Metformin has been used in pharmacotherapy since 1950s and nowadays it is considered to be the drug of choice in the treatment of type 2 diabetes. Metformin owns this remarkable status mainly due to its efficacy and good tolerance. Its unique mechanism of action can directly affect the pathomechanism of type 2 diabetes. It is also becoming increasingly apparent that metformin usage is associated with additional benefits resulting from its pleiotropic mechanisms of action, resulting in clinical benefits not only of antihyperglycaemic effects.
Article Details
How to Cite
Łabuzek, K., & Okopień, B. (2015). 4 reasons to use metformin. Medycyna Faktow (J EBM), 8(2(27), 24-29. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2307
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2014. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2014; 3(supl. A).
2. Dinneen S., Gerich J., Rizza R.: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1992; 327(10): 707-713.
3. Cusi K., Consoli A., DeFronzo R.A.: Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1996; 81: 4059-4067.
4. Hundal R.S., Krssak M., Dufour S. et al.: Mechanism by which metformin reduces glucose production in type 2 diabetes mellitus. Diabetes 2000; 49: 2063-2069.
5. Giannarelli R., Aragona M., Coppelli A. et al.: Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003; 29(4 Pt 2): 6S28-35.
6. Viollet B., Guigas B., Sanz Garcia N. et al.: Cellular and molecular mechanisms of metformin: an overview. Clin. Sci (Lond) 2012; 122(6): 253-270.
7. El-Mir M.Y., Nogueira V., Fontaine E. et al.: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000; 275: 223-228.
8. Zhou G., Myers R., Li Y. et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108: 1167-1174.
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998; 352: 854-865.
10. Wright A.D., Cull C.A., Macleod K.M. et al.; UKPDS Group: Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J. Diabetes Complications 2006; 20(6): 395-401.
11. Bailey C.J., Wilcock C., Scarpello J.H.: Metformin and the intestine. Diabetologia 2008; 51: 1552-1553.
12. Scarpello J.H., Howlett H.C.: Metformin therapy and clinical uses. Diab. Vasc. Dis. Res 2008; 5: 157-167.
13. Cusi K., DeFronzo R.A.: Metformin: a review of its metabolic effects. Diabetes Rev. 1998; 6: 89-131.
14. Hirst J.A., Farmer A.J., Ali R. et al.: Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012; 35(2): 446-454.
15. Sieradzki J.: Cukrzyca. Via Medica, Gdańsk 2006: 445-447.
16. Salpeter S.R., Greyber E., Pasternak G.A. et al.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Archives of Internal Medicine 2003; 163: 2594-2602.
17. Wytyczne ESC dotyczące cukrzycy, stanu przedcukrzycowego i chorób układu sercowo-naczyniowego opracowane we współpracy z EASD. Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw cukrzycy, stanu przedcukrzycowego i chorób układu sercowo-naczyniowego we współpracy z Europejskim Towarzystwem Badań nad Cukrzycą (EASD). Kardiologia Polska 2013; 71: 365-368.
18. Eurich D.T., McAlister F.A., Blackburn D.F. et al.: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335(7618): 497.
19. Aguilar D., Chan W., Bozkurt B. et al.: Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ. Heart Fail. 2011; 4(1): 53-58.
20. Duong J.K., Kumar S.S., Kirkpatrick C.M. et al.: Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin. Pharmacokinet. 2013; 52(5): 373-384.
21. Knowler W.C., Barrett-Connor E., Fowler S.E. et al.; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346(6): 393-403.
22. Lily M., Godwin M.: Treating prediabetes with metformin systematic review and meta-analysis. Can. Fam. Physician 2009; 55: 363-369.
23. Salpeter S.R., Buckley N.S., Kahn J.A. et al.: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 2008; 121(2): 149-157.
24. Giovannucci E., Harlan D.M., Archer M.C. et al.: Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685.
25. Evans J.M., Donnelly L.A., Emslie-Smith A.M. et al.: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330(7503): 1304-1305.
26. Landman G.W., Kleefstra N., van Hateren K.J. et al.: Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33(2): 322-326.
27. Bowker S.L., Majumdar S.R., Veugelers P. et al.: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29(2): 254-258.
28. Chen H.P., Shieh J.J., Chang C.C. et al.: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013; 62(4): 606-615.
29. Wright J.L., Stanford J.L.: Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009; 20(9): 1617-1622.
30. Aljada A., Mousa S.A.: Metformin and neoplasia: implications and indications. Pharmacol. Ther. 2012; 133: 108-115.
31. Wulffele M.G., Kooy A., de Zeeuw D. et al.: The effect of metformin on blood pressure, plasma cholesterol and triglicerides in type 2 diabetes mellitus: a systematic review. J. Intern. Med. 2004; 256: 1-14.
32. Schwartz S., Fonseca V., Berner B. et al.: Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29: 759-764.
2. Dinneen S., Gerich J., Rizza R.: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1992; 327(10): 707-713.
3. Cusi K., Consoli A., DeFronzo R.A.: Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1996; 81: 4059-4067.
4. Hundal R.S., Krssak M., Dufour S. et al.: Mechanism by which metformin reduces glucose production in type 2 diabetes mellitus. Diabetes 2000; 49: 2063-2069.
5. Giannarelli R., Aragona M., Coppelli A. et al.: Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003; 29(4 Pt 2): 6S28-35.
6. Viollet B., Guigas B., Sanz Garcia N. et al.: Cellular and molecular mechanisms of metformin: an overview. Clin. Sci (Lond) 2012; 122(6): 253-270.
7. El-Mir M.Y., Nogueira V., Fontaine E. et al.: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000; 275: 223-228.
8. Zhou G., Myers R., Li Y. et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108: 1167-1174.
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998; 352: 854-865.
10. Wright A.D., Cull C.A., Macleod K.M. et al.; UKPDS Group: Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J. Diabetes Complications 2006; 20(6): 395-401.
11. Bailey C.J., Wilcock C., Scarpello J.H.: Metformin and the intestine. Diabetologia 2008; 51: 1552-1553.
12. Scarpello J.H., Howlett H.C.: Metformin therapy and clinical uses. Diab. Vasc. Dis. Res 2008; 5: 157-167.
13. Cusi K., DeFronzo R.A.: Metformin: a review of its metabolic effects. Diabetes Rev. 1998; 6: 89-131.
14. Hirst J.A., Farmer A.J., Ali R. et al.: Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012; 35(2): 446-454.
15. Sieradzki J.: Cukrzyca. Via Medica, Gdańsk 2006: 445-447.
16. Salpeter S.R., Greyber E., Pasternak G.A. et al.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Archives of Internal Medicine 2003; 163: 2594-2602.
17. Wytyczne ESC dotyczące cukrzycy, stanu przedcukrzycowego i chorób układu sercowo-naczyniowego opracowane we współpracy z EASD. Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw cukrzycy, stanu przedcukrzycowego i chorób układu sercowo-naczyniowego we współpracy z Europejskim Towarzystwem Badań nad Cukrzycą (EASD). Kardiologia Polska 2013; 71: 365-368.
18. Eurich D.T., McAlister F.A., Blackburn D.F. et al.: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335(7618): 497.
19. Aguilar D., Chan W., Bozkurt B. et al.: Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ. Heart Fail. 2011; 4(1): 53-58.
20. Duong J.K., Kumar S.S., Kirkpatrick C.M. et al.: Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin. Pharmacokinet. 2013; 52(5): 373-384.
21. Knowler W.C., Barrett-Connor E., Fowler S.E. et al.; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346(6): 393-403.
22. Lily M., Godwin M.: Treating prediabetes with metformin systematic review and meta-analysis. Can. Fam. Physician 2009; 55: 363-369.
23. Salpeter S.R., Buckley N.S., Kahn J.A. et al.: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 2008; 121(2): 149-157.
24. Giovannucci E., Harlan D.M., Archer M.C. et al.: Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685.
25. Evans J.M., Donnelly L.A., Emslie-Smith A.M. et al.: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330(7503): 1304-1305.
26. Landman G.W., Kleefstra N., van Hateren K.J. et al.: Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33(2): 322-326.
27. Bowker S.L., Majumdar S.R., Veugelers P. et al.: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29(2): 254-258.
28. Chen H.P., Shieh J.J., Chang C.C. et al.: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013; 62(4): 606-615.
29. Wright J.L., Stanford J.L.: Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009; 20(9): 1617-1622.
30. Aljada A., Mousa S.A.: Metformin and neoplasia: implications and indications. Pharmacol. Ther. 2012; 133: 108-115.
31. Wulffele M.G., Kooy A., de Zeeuw D. et al.: The effect of metformin on blood pressure, plasma cholesterol and triglicerides in type 2 diabetes mellitus: a systematic review. J. Intern. Med. 2004; 256: 1-14.
32. Schwartz S., Fonseca V., Berner B. et al.: Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29: 759-764.